The cardiovascular system medicine sales in Japan are projected to decrease steadily from 2024 to 2028, with values declining from 830.03 billion yen in 2024 to 739.62 billion yen in 2028. This represents an average year-on-year decrease, reflecting a negative CAGR over these years. The decline suggests a shrinking market potentially driven by factors such as increased generic drug uptake, declining patient numbers due to Japan's aging population, or effective health management strategies reducing disease prevalence.

Future trends to watch for include:

Advancements in cardiovascular health technology and their impact on medicine demand.
The influence of government policies on healthcare spending and drug pricing.
Potential demographic shifts that could alter demand patterns.